Blood test markers to predict outcomes in acute myeloid leukemia
Part of Blood & lymphatic, Cancer clinical trials.
This study looks at whether certain blood test levels (ferritin, and two ratios called CAR and AFR) can help predict how patients with a type of leukemia called AML (non-M3) will do. The goal is to find clues that may guide future treatment decisions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have been newly diagnosed with acute myeloid leukemia (AML), not the M3 subtype.
- This is your first diagnosis — not a relapse.
- You have not had previous chemotherapy or radiation for this cancer.
- You have not had a blood transfusion before this diagnosis.
- You do not have significant heart, liver, or kidney problems, and do not have diabetes with nerve damage.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at certain proteins in the blood (called FLT3 ligand and IL6) of people being treated for blood cancers like AML, MDS, or CMML. The goal is to understand how these proteins change during non-intensive chemotherapy, which may help doctors better personalize treatment.
This study tests a new lab method to screen for acute myeloid leukemia (AML), including a rare subtype called acute promyelocytic leukemia. It may help doctors diagnose and classify AML more quickly and accurately.
This study looks at whether the ratio of platelets to white blood cells in your blood can help predict how the disease will progress. It's a simple blood test that might give doctors more information about your AML.
This study uses a special blood test (flow cytometry) to look for leukemia stem cells in your blood and bone marrow. The goal is to see if these cells can help predict if leukemia will come back after treatment, which might lead to better care for children and teens with AML.
This study looks at whether a simple blood test that measures tumor DNA (called ctDNA) can track how well treatment is working in children with acute leukemia. The goal is to see if the blood test can give the same information as a bone marrow test, which is more invasive.
This study looks at special markers in bone marrow fluid to predict how well chemotherapy will work for newly diagnosed acute myeloid leukemia (AML). By identifying these markers early, doctors may be able to choose the best treatment plan for each patient.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.